Tightening its wallet for a clinical comeback, Seres lets go of CSO and 30% of workforce
Two weeks after moving to the helm of Seres Therapeutics from the CFO office, Eric Shaff has been charged with the unenviable task of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
